Rekah Pharmaceutical Industry Ltd.

ILA 1,028As of Sun 8 Nov 2026, 12:00 UTC
TASE:REKAHealthcare
Country Israel
PE (Fwd) •••
TSR 10Y CAGR (6.81%)
Div yield —
ROE (10.69%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.12
PE TTM —
TSR TTM (12.36%)
Mkt cap ILS 117.3M
ROIC (2.60%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
ILA 1,336
29.92%
(47.17%)
Buy 10|0|4|5|2
4Q25
1Q26
2Q26
3Q26
Earnings per shareILS
10.30
10.25
10.07
9.92
23.37%
17.08%
4.63%
7.21%
RevenueILS M
5.149
5.245
5.363
5.489
(0.89%)
2.33%
6.28%
7.18%
Peers (US$36.20M)
Cap (US$)
PE
38.71M
—
Capital
TTM
5Y
10Y
Leveragex
2.168
2.554
1.892
EBIT/Intx
0.473
2.753
3.081
Own earn%
(27.63)
(69.20)
(36.84)
Sh yield%
55.00
36.53
36.12
Owners
Insiders/Inst%
4.95
47.07
Short interest%
3.20
SBC / revenue%
2.92
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
22–27
$1 testx
0.0
Incr. ROIC%
3